News

These findings suggest the need for additional clinical evaluations in trials on a larger scale to allow for confirmation of the efficacy and safety of the treatment.

Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.

This new data may help to indicate a potential common immunological mechanism, allowing for greater assessment of the effects of therapeutic agents and treatment combinations.

While specialists still debate the diagnostics of impaired cognition, the identification of patients at the earliest stages is beginning to be met through new biomarkers and available assays.

The decision was based on both clinical and non-clinical data supporting the biosimilarity of bevacizumab-tnjn (Avzivi), previously named BAT1706.

Using data from the 2017-2020 NHANES, investigators found high copper intake and moderate iron intake were associated with a decreased risk of MAFLD.

Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?

The seroprevalence of HCV antibody among pregnant women was significantly greater among those with opioid use disorder and HIV infection, as well as in lower-middle-income countries and those with low levels of HDI.

Increases in the working-age population during the 30-year period may have contributed to the global burden of visual impairment

These new findings represent the only PTC case to look at such a unique number of concurrent comorbidities in current medical literature.

The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.

These phase 2 data indicate that the implant may be a helpful addition to clinicians’ interventional glaucoma armamentarium for patients.

Significant increases in macular and choroidal thickness were observed in the fovea and perifovea at all postoperative visits in patients with diabetic retinopathy.

Positive topline results from the phase 2 trial indicate EYP-1901 exhibited statistical non-inferiority in BCVA to aflibercept, with a favorable safety profile.

Results from a systematic review highlighted the clinical need for specific biomarkers for PAD and the viability of noninvasive ophthalmic imaging techniques for diagnosis.

A substudy of the ASCEND trial offers insight into the effects of omega-3 fatty acids use on risk of diabetic retinopathy in people with diabetes.

In a new study, inserting the XEN-45 implant in patients with uncontrolled uveititc glaucoma prevented conventional glaucoma surgery in 83.3% of patients.

Investigators observed differences in choroidal and inner neural layers among patients previously infected with COVID-19 compared to healthy controls.

A systematic review and meta-analysis provides insight into the potential for increased risk of noninfectious uveitis among people with vitamin D deficiency.

Pinkerton reflects on the breakthrough approval for the non-estrogen, non-hormonal daily oral drug earlier this year.

The review emphasized the importance of therapies that provide sustained visual outcomes, given the increasing incidence of nAMD among aging adults.

During this interview, Perkins described a recent landmark study which yielded some unique findings regarding pathogen-detection.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

SIRI emerged as a significant factor influencing acute gout attacks, shedding light on a prospective diagnostic tool.

The final quarterly issue of the year touches on head-to-head trial data, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest ACG recommendations for Celiac disease.e.

An expert reviews the updated recommendations of the American College of Gastroenterology guidelines on the evaluation and management of celiac disease.

While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.

Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.

The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.